ALT5 Sigma (NASDAQ:AIFC) Releases Quarterly Earnings Results

ALT5 Sigma (NASDAQ:AIFC) posted its quarterly earnings results on Monday. The company reported $0.42 EPS for the quarter, Zacks reports. ALT5 Sigma had a negative return on equity of 68.25% and a negative net margin of 2,483.94%.

ALT5 Sigma Trading Up 3.9%

Shares of NASDAQ AIFC traded up $0.02 during midday trading on Monday, reaching $0.42. 1,085,552 shares of the company were exchanged, compared to its average volume of 2,509,992. The stock’s 50-day moving average price is $0.54 and its 200-day moving average price is $0.98. ALT5 Sigma has a one year low of $0.36 and a one year high of $8.74. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.82 and a current ratio of 0.82.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ALT5 Sigma in a research report on Tuesday, July 14th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ALT5 Sigma presently has an average rating of “Sell”.

Institutional Investors Weigh In On ALT5 Sigma

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in ALT5 Sigma by 775.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,126,395 shares of the company’s stock worth $16,480,000 after purchasing an additional 5,426,519 shares in the last quarter. Prelude Capital Management LLC acquired a new stake in shares of ALT5 Sigma during the third quarter valued at about $6,216,000. NWI Management LP acquired a new stake in shares of ALT5 Sigma during the third quarter valued at about $4,842,000. Alyeska Investment Group L.P. bought a new stake in shares of ALT5 Sigma during the third quarter worth about $4,697,000. Finally, Geode Capital Management LLC grew its holdings in shares of ALT5 Sigma by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 1,331,963 shares of the company’s stock worth $1,466,000 after purchasing an additional 12,400 shares during the last quarter. Institutional investors and hedge funds own 6.27% of the company’s stock.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.